Clinical trials: Cisplatin
Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram
Treatment of Advance Gastric Cancer With Disulfiram
Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main chemotherapy drug. However, there are many adverse reactions, including bone marrow suppression, gastrointestinal reactions, renal toxicity…
- Trial name
- NCT05667415
- Testing
- disulfiram and cisplatin, cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First People's Hospital of Hangzhou
Cholangiocarcinoma, Biliary Tract Cancer
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
There is no proven adjuvant treatment after curative surgical resection in patients with cholangiocarcinoma, although previous meta-analysis suggested potential survival benefit of adjuvant chemotherapy or radiotherapy in…
- Conditions
- Cholangiocarcinoma, Biliary Tract Cancer, Adjuvant Chemotherapy, Capecitabine
- Trial name
- NCT03079427
- Testing
- Gemcitabine plus cisplatin, Capecitabine
- Where
- South Korea
- Volunteers
- 101 people
- Sponsor
- Asan Medical Center
HER2-negative Breast Cancer, Neoadjuvant Therapy
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
The achievement of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with improved outcome across all breast cancer (BC) subtypes.
- Conditions
- HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response, Immunotherapy
- Trial name
- NCT04848454
- Testing
- Camrelizumab with vinorelbine and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Cisplatin Adverse Reaction
Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity
Approximately one-third of all patients treated with cisplatin develop renal dysfunction after a single dosage of cisplatin. Germline genetic polymorphisms may cause variations in cisplatin pharmacokinetics and in the ability of…
- Trial name
- NCT05247671
- Testing
- ERCC1, OCT2
- Where
- Egypt
- Volunteers
- 89 people
- Sponsor
- Ain Shams University
Cisplatin-Induced Hearing Loss in Children Who Had Standard-risk Hepatoblastoma
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
This is a CUP which is designed to provide treatment access of STS to pediatric patients for the protection from Cisplatin-Induced Hearing Loss in children who had standard-risk hepatoblastoma.
- Trial name
- NCT04132882
- Testing
- Sodium Thiosulfate (STS)
- Where
- Turkey (Türkiye)
- Sponsor
- TRPHARM
Urothelial Carcinoma, Anlotinib
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first…
- Conditions
- Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms, Cisplatin
- Trial name
- NCT05030077
- Testing
- Anlotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Adenoid Cystic Carcinomas, Cisplatin
Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)
The investigators conducted this study to evaluate the efficacy of Chidamide combined with cisplatin in recurrent or metastatic head and neck adenoid cystic carcinoma.
- Trial name
- NCT03639168
- Testing
- Chidamide combined with cisplatin
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Cisplatin Adverse Reaction
Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity
Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans. Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity and ototoxicity of the drug makes it…
- Trial name
- NCT04817904
- Testing
- Rosuvastatin 10mg
- Where
- Egypt
- Volunteers
- 65 people
- Sponsor
- Cairo University
Cisplatin Induced Hearing Loss
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of…
- Trial name
- NCT02997189
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Otonomy, Inc.
Cisplatin Ototoxicity, Hearing Loss
Randomized Trial Comparison of Ototoxicity Monitoring Programs
This study involves research. Some chemotherapeutic drugs that can permanently reduce hearing are termed "ototoxic". One such drug is the chemotherapy called cisplatin.
- Trial name
- COMP-VA (NCT02099786)
- Testing
- COMP-VA, Standard of care
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cisplatin Adverse Reaction, Hearing Loss Ototoxic
Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer
Introduction. Cisplatin-induced ototoxicity is a very frequent event and its consequences can cause a lot of deterioration in patients.
- Trial name
- NCT03400709
- Testing
- N Acetylcysteine
- Where
- Chile
- Volunteers
- 45 people
- Sponsor
- Hospital San Juan de Dios, Santiago
Chidamide, Lymphoma, B-Cell
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The goal of this clinical trial is to evaluate therapeutic efficacy of Chidamide combined with R-GDP （rituximab/gemcitabine/dexamethasone/cisplatin）in treating Patients with relapsed or refractory Diffuse Large B-cell Lymphoma…
- Conditions
- Chidamide, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm by Histology
- Trial name
- NCT03373019
- Testing
- Chidamide combined with R-GDP
- Where
- 2 sites in China
- Volunteers
- 63 people
- Sponsor
- Fudan University
First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
Until today, the 5-FU/cisplatin combination is the reference regimen with 30-45% response rates, which is most commonly used to treat patients with metastatic, recurrent or locally advanced, unresectable squamous cell carcinoma…
- Conditions
- First Line Chemotherapy, Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel, Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Trial name
- XP versus XT (NCT00816634)
- Testing
- Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Samsung Medical Center
Cisplatin Nephrotoxicity
Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity
Cisplatin is a major anti-neoplastic drug used for the treatment of solid tumors. Its chief dose limiting side effect is nephrotoxicity. Twenty percent of patients receiving high-dose cisplatin undergo severe renal dysfunction.
- Trial name
- NCT02760901
- Testing
- Acetazolamide, Acetylcysteine, Mannitol
- Volunteers
- 52 people
- Sponsor
- Ain Shams University
Cancer, Cisplatin Adverse Reaction
Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury
Cisplatin is a potent chemotherapeutic agent, however, its nephrotoxicity manifested by acute kidney injury (AKI) often limits applicability.
- Trial name
- NCT02250872
- Testing
- Gemigliptin, Cisplatin
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Bundang Hospital
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Upper GI Cancer, Cisplatin Adverse Reaction
Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma
Cisplatin is a potent chemotherapeutic agent that has been widely used to treat many solid tumours. acute renal failure, despite conservative fluid and electrolyte management, frequently reported adverse event and limiting…
- Trial name
- NCT01829178
- Testing
- Silymarin, chemotherapy
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Tehran University of Medical Sciences
Cisplatin Ototoxicity
Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment
Cisplatin is a widely used chemotherapeutic agent for the treatment of various malignant neoplasms, including testicular, ovarian, bladder, cervix uteri, head and neck and lung cancers.
- Trial name
- NCT01372904
- Testing
- Dexamethasone Phosphate
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Meir Medical Center
Vomiting, Cisplatin Adverse Reaction
Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy
Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy induced emesis.
- Trial name
- NCT01052844
- Testing
- Gabapentin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Faculdade de Medicina do ABC
Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)
Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment
In Spain, the gastric carcinoma is the 5th most frequent malignant tumor in women and the 6th in men, and represents the 3rd cause of cancer-related deaths amongst women and the 4th amongst men.
- Trial name
- NCT01262482
- Testing
- Oxaliplatin, Sorafenib
- Where
- 10 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo